Summary of Key Points Company Overview - The document discusses Guotai Haitong Pharmaceutical's drug, Iza Bren, which is an EGFR*HER3 dual-target antibody-drug conjugate (ADC) [1] Core Insights and Arguments - Iza Bren has successfully reached both progression-free survival (PFS) and overall survival (OS) endpoints in a Phase III clinical trial for second-line treatment of triple-negative breast cancer (TNBC) after chemotherapy failure [1] - This marks the first indication for Iza Bren to achieve the OS endpoint, highlighting its superior efficacy [1] - Previously, Iza Bren has also met the PFS endpoint in Phase III clinical trials for second-line nasopharyngeal carcinoma (NPC) and esophageal squamous cell carcinoma (ESCC) in China [1] - The company anticipates that Iza Bren will complete an additional 3-4 Phase III clinical trials in China within the year [1] Additional Important Information - The successful clinical trial results may position Iza Bren favorably in the competitive oncology market, potentially leading to increased market share and revenue for Guotai Haitong Pharmaceutical [1]